北京博晖创新生物技术股份有限公司 2021 年第一季度报告全文 北京博晖创新生物技术股份有限公司 2021 年第一季度报告 定 2021-03 2021 年 04 月 1 北京博晖创新生物技术股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人翟晓枫、主管会计工作负责人董海锋及会计机构负责人(会计主 管人员)李娟声明：保证季度报告中财务报表的真实、准确、完整。 2 北京博晖创新生物技术股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 159,118,438.30 | 139,506,502.75 | 14.06% | | 归属于上市公司股东的净利润（元） | -10,471,465.66 | -13,453,68 ...

Financial Performance - The company's operating revenue for 2020 was ¥738,717,388.06, representing a 17.57% increase compared to ¥628,340,031.11 in 2019[18]. - The net profit attributable to shareholders for 2020 was ¥7,503,976.45, a significant increase of 195.11% from ¥2,542,755.03 in 2019[18]. - The net cash flow from operating activities improved to ¥86,137,577.29, a 339.09% increase from -¥36,027,044.31 in 2019[18]. - The total assets at the end of 2020 reached ¥3,715,242,196.65, marking a 37.88% increase from ¥2,694,604,343.18 at the end of 2019[18]. - The net assets attributable to shareholders increased by 26.04% to ¥1,299,959,538.30 from ¥1,031,395,597.18 in 2019[18]. - The basic earnings per share for 2020 was ¥0.0092, up 196.77% from ¥0.0031 in 2019[18]. - The weighted average return on net assets was 0.72% for 2020, an increase from 0.22% in 2019[18]. - The company reported a net profit excluding non-recurring gains and losses of ¥3,859,539.32, compared to a loss of -¥11,324,129.26 in 2019, reflecting a 134.08% improvement[18]. - The company achieved a total revenue of CNY 738.72 million in 2020, representing a year-on-year growth of 17.57%[67]. - Net profit attributable to shareholders reached CNY 7.50 million, a significant increase of 195.11% compared to the previous year[59]. Revenue and Sales - The company's operating revenue for 2020 was CNY 139.51 million, a decrease from CNY 227.96 million in 2019, representing a decline of approximately 38.8%[21]. - The net profit attributable to shareholders was a loss of CNY 13.45 million in 2020, compared to a profit of CNY 21.65 million in 2019, indicating a significant downturn[21]. - The in vitro diagnostic business saw a revenue decline of 8.77%, totaling CNY 282.09 million, with reagent sales down by 12.26%[67]. - The biopharmaceutical business reported a revenue of CNY 441.09 million, marking a 43.98% increase, driven by the consolidation of Zhongke Biology and increased vaccine sales[61]. - The company’s blood product sales model includes both distribution and direct sales, targeting hospitals and pharmaceutical distribution enterprises[34]. - The company’s human rabies vaccine is sold directly to disease prevention and control centers nationwide[34]. - The company reported a gross margin of 39.19% for its biopharmaceutical business, an increase of 10.08% year-on-year[70]. Market and Industry Insights - The global in vitro diagnostics (IVD) market was valued at $64 billion in 2019, with a year-on-year growth of 5%[38]. - The Chinese IVD market exceeded RMB 115 billion (over $17 billion) in 2019, growing approximately 15% year-on-year[39]. - The domestic market for molecular diagnostics is one of the fastest-growing segments, accounting for about 20% of the overall IVD market[40]. - The market share of domestic products in the immunology sector is approximately 25%-30%, while biochemical diagnostics exceed 50%[41]. - The blood products industry is experiencing consolidation, with the top five companies holding 80%-85% of the market share globally[45]. - The domestic IVD industry is characterized by a low concentration, with over 600 companies, and the top 20 companies holding only about 30% market share[42]. - The blood products industry in China has high barriers to entry and strict regulations, with significant oversight on plasma collection and product quality[46]. - The domestic market for blood products has substantial growth potential, with the average consumption of immunoglobulin and coagulation factor products in developed countries far exceeding that of China[47]. Research and Development - The company has developed over 20 patents related to its unique microfluidic nucleic acid chip technology, which is a key driver for its HPV testing products[29]. - The company is actively involved in the research and development of vaccines, including human rabies vaccines, expanding its product offerings in the biological products sector[33]. - The company has initiated the development of a new qPCR platform that enhances detection sensitivity and reduces testing time[82]. - The company has completed the prototype manufacturing of a new atomic fluorescence spectrometer, meeting all acceptance criteria[84]. - The company is expanding its product line with new nucleic acid testing kits, including those for COVID-19 and respiratory pathogens, expected to launch in the next two to three years[85]. - The company has invested approximately 36.18 million yuan in the research and development of blood products during the reporting period[86]. - The company aims to enhance the comprehensive utilization of plasma resources to improve product competitiveness[86]. - The R&D investment as a percentage of operating revenue for the past three years indicates a consistent commitment to innovation and product development[87]. - The company reported a significant increase in R&D spending compared to previous years, with a total of ¥76,140,363.67 in 2020[88]. Cash Flow and Financing - The net cash flow from operating activities increased by 339.09% to ¥86,137,577.29 compared to a net outflow of ¥36,027,044.31 in the previous year[94]. - Total cash inflow from operating activities was ¥788,361,005.62, reflecting a year-on-year increase of 13.37%[94]. - Cash inflow from financing activities rose by 192.75% to ¥2,953,185,035.69, primarily due to a prepayment of ¥1.122 billion from a development company[95]. - The net cash flow from financing activities also increased by 207.00% to ¥288,773,772.76[94]. - Investment activities saw a significant cash inflow increase of 37,043.93% to ¥769,510,828.12, attributed to cash recovered from short-term financial management[95]. - The company reported a net increase in cash and cash equivalents of ¥13,176,556.93, a turnaround from a decrease of ¥72,502,275.21 in the previous year, marking an increase of 118.17%[94]. Corporate Governance and Compliance - The company guarantees that all information provided during the transaction process is true, accurate, and complete, with no false records or misleading statements[144]. - The company has fulfilled its legal disclosure and reporting obligations, with no undisclosed contracts, agreements, arrangements, or other matters[145]. - The company has not been subject to any major administrative penalties or criminal sanctions in the last thirty-six months[146]. - The company has committed to providing true, accurate, and complete original written materials to all intermediary institutions involved in the transaction[145]. - The company has not participated in any major asset restructuring that is prohibited by regulations in the last thirty-six months[145]. - The company has undertaken to bear all legal responsibilities for any economic losses or claims arising from violations of the commitments made[146]. Future Outlook and Strategic Plans - The company provided a future outlook, projecting a revenue growth of 25% for the next fiscal year, driven by new product launches and market expansion strategies[147]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[147]. - The company aims to enhance its core competitiveness through increased R&D investment in its testing and detection business[143]. - The company plans to continue increasing its market development efforts alongside R&D for new products[140]. - The company aims to implement a new customer engagement strategy, which is projected to improve customer retention rates by 30%[147]. Asset Management and Investments - The company has entrusted RMB 752.5 million in bank wealth management products, with no overdue amounts reported[189]. - The company plans to use up to RMB 580 million of idle funds for cash management through bank wealth management products[196]. - The company approved a total credit limit of up to RMB 580 million for comprehensive financing from banks and financial institutions[197]. - The company signed a comprehensive credit contract with Beijing Bank for a maximum credit limit of RMB 30 million[198]. Rental Income and Property Management - The company reported rental income of 2.047 million yuan from properties located in Beijing during the reporting period[178]. - The company generated rental income of 7.1275 million yuan from temporarily idle properties in Beijing during the reporting period[178]. - The total rental income from the properties contributed over 10% to the company's total profit for the reporting period[178]. - The company has a lease agreement with Zhongguancun Life Science Park Development Co., Ltd. for office space, generating a rental income of 3.1442 million yuan[178].

北京博晖创新生物技术股份有限公司 2020 年第三季度报告全文 北京博晖创新生物技术股份有限公司 1 北京博晖创新生物技术股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人翟晓枫、主管会计工作负责人董海锋及会计机构负责人(会计主 管人员)李娟声明：保证季度报告中财务报表的真实、准确、完整。 2 北京博晖创新生物技术股份有限公司 2020 年第三季度报告全文 2020 年第三季度报告 定 2020-06 2020 年 10 月 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 3,668,429,687.48 | 2,694,604,343.18 | | 36.14% | | 归属 ...

北京博晖创新生物技术股份有限公司 2020 年半年度报告全文 北京博晖创新生物技术股份有限公司 2020 年半年度报告 定 2020-04 2020 年 08 月 1 北京博晖创新生物技术股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人翟晓枫、主管会计工作负责人董海锋及会计机构负责人(会计主 管人员)李娟声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 目录 | | --- | | 2020 | 年半年度报告 2 | | --- | --- | | 第一节 | 重要提示、目录和释义 2 | | 第二节 | 公司简介和主要财务指标 5 | | 第三节 | 公司业务概要 8 | | 第四节 | 经营情况讨论与分析 275 | | 第五节 | 重要事项 27 | | 第六节 | 股份变动及股东情况 35 | | 第七节 ...

北京博晖创新生物技术股份有限公司 2020 年第一季度报告全文 北京博晖创新生物技术股份有限公司 2020 年第一季度报告 定 2020-03 2020 年 04 月 1 北京博晖创新生物技术股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 139,506,502.75 | 134,580,507.88 | 3.66% | | 归属于上市公司股东的净利润（元） | -13,453,684.69 | -6,281,688.10 | -114.17% | | 归属于上市公司股东的扣除非经常性损 益的净利润（元） | -12,772,384.53 | -6,238,719.03 | -104.73% | | 经营活动产生的现金流量净额（元） | 21,810,011. ...

Financial Performance - Operating revenue for the reporting period was CNY 167,780,231.32, an increase of 4.70% year-on-year[8] - Net profit attributable to shareholders decreased by 47.21% to CNY 3,267,994.90[8] - Basic earnings per share were CNY 0.0040, down 47.37% compared to the same period last year[8] - Investment income for the period was CNY 156.52 million, reflecting a decrease from the previous year's CNY 352.18 million due to the recognition of equity compensation[20] - The total profit for the current period was ¥5,745,043.85, down from ¥11,139,909.37 in the previous period[42] - The net profit for Q3 2019 was CNY 8,627,171.12, a decrease of 69.9% from CNY 28,721,165.26 in the same period last year[50] - Comprehensive income for the current period totaled ¥3,981,748.75, down from ¥10,663,042.87 in the previous period[42] - The company's operating revenue for Q3 2019 was CNY 162,371,553.11, an increase of 8.3% compared to CNY 149,979,806.56 in Q3 2018[53] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,648,914,362.58, a decrease of 2.34% compared to the end of the previous year[8] - The company's total liabilities reached CNY 1,603,565,767.16, up from CNY 1,468,410,939.03, indicating a rise of 9.2%[33] - Current liabilities totaled CNY 1,264,644,733.62, compared to CNY 1,252,671,478.33 in the previous period, reflecting an increase of approximately 1.5%[33] - Long-term borrowings increased significantly to CNY 217,544,859.15 from CNY 106,100,000.00, representing a growth of 104.1%[33] - Cash and cash equivalents decreased by 75.10% compared to the beginning of the year, primarily due to a reduction in available working capital[19] - Cash and cash equivalents at the end of the period decreased to 25,521,698.75 CNY from 58,968,392.31 CNY, indicating a decline in liquidity[58] Shareholder Information - The company reported a total of 18,987 common shareholders at the end of the reporting period[12] - The top shareholder, Du Jiangtao, holds 39.03% of the shares, amounting to 318,811,388 shares[12] - The total equity attributable to shareholders decreased to CNY 1,019,953,617.76 from CNY 1,173,270,705.96, a decline of 13.1%[34] Cash Flow - The net cash flow from operating activities was CNY -43,150,496.29, a decrease of 30.56% year-on-year[8] - Cash flow from operating activities increased to CNY 510,538,187.72, compared to CNY 423,216,336.39 in Q3 2018[56] - Total cash inflow from financing activities increased to 657,376,480.66 CNY, compared to 366,786,408.00 CNY in the prior period, reflecting a significant rise in borrowing[58] - The total cash outflow for financing activities was 584,085,726.01 CNY, significantly higher than 267,100,332.36 CNY in the previous period, reflecting increased financial obligations[58] Expenses and Costs - Total operating costs increased to ¥160,986,669.70, up 7.9% from ¥149,145,891.68 in the previous period, with operating costs specifically rising to ¥86,500,089.70 from ¥77,413,394.21[41] - Financial expenses increased by CNY 4.30 million, a rise of 31.13%, mainly due to increased interest expenses from higher borrowings[20] - The company paid 160,698,149.87 CNY to employees, an increase from 131,378,035.09 CNY, reflecting higher labor costs[57] Research and Development - The company reported a significant increase in research and development expenses, totaling ¥13,008,593.64, compared to ¥12,952,626.87 in the previous period[41] - Research and development expenses rose to CNY 39,246,495.87, up 11.8% from CNY 35,089,152.21 in Q3 2018[53] Future Outlook - The company expects a significant decline in cumulative net profit compared to the same period last year, primarily due to reduced impacts from equity compensation and goodwill impairment[23] - The company plans to continue focusing on R&D and market expansion to improve future performance[50]

北京博晖创新生物技术股份有限公司 2019 年半年度报告全文 北京博晖创新生物技术股份有限公司 2019 年半年度报告 定 2019-04 2019 年 08 月 1 北京博晖创新生物技术股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人卢信群、主管会计工作负责人牛树荟及会计机构负责人(会计主 管人员)李娟声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 2019 | 年半年度报告 1 | | --- | --- | | 第一节 | 重要提示、释义 1 | | 第二节 | 公司简介和主要财务指标 4 | | 第三节 | 公司业务概要 6 | | 第四节 | 经营情况讨论与分析 10 | | 第五节 | 重要事项 14 | | 第六节 | 股份变动及股东情况 15 | | 第七节 | 优先股相关情况 16 ...

Financial Performance - Total revenue for Q1 2019 was ¥134,580,507.88, an increase of 4.62% compared to ¥128,637,899.74 in the same period last year[8] - Net profit attributable to shareholders was -¥6,281,688.10, a decrease of 183.42% from ¥7,530,601.21 in the previous year[8] - Basic earnings per share decreased by 183.70% to -¥0.0077 from ¥0.0092 in the same period last year[8] - Operating income increased by 4.62% year-on-year, with the parent company benefiting from an 18% increase in microfluidic product revenue[23] - The company reported a net operating loss of CNY -3,311,283.65 for Q1 2019, compared to a profit of CNY 10,316,428.21 in the previous year[41] - The net profit for Q1 2019 was a loss of CNY 4,365,383.99, compared to a profit of CNY 8,326,652.67 in Q1 2018, indicating a significant decline[43] - The total comprehensive income for Q1 2019 was a loss of CNY 5,010,249.33, compared to a gain of CNY 7,149,405.62 in Q1 2018[43] Cash Flow - Net cash flow from operating activities was -¥46,907,435.82, a decline of 27.37% compared to -¥36,828,618.07 in the previous year[8] - Cash flow from operating activities related to other payments increased by 59.56% year-on-year, attributed to higher sales and R&D expenses[21] - The operating cash flow for Q1 2019 was a net outflow of CNY 46,907,435.82, worsening from a net outflow of CNY 36,828,618.07 in the same period last year[50] - The net cash flow from operating activities was -20,815,200.73 RMB, compared to -6,609,913.82 RMB in the previous period, indicating a significant decline in operational cash flow[53] - The company received cash inflows from financing activities totaling 124,285,772.43 RMB, while cash outflows were 71,305,715.68 RMB, resulting in a net cash flow of 52,980,056.75 RMB from financing activities[51] - Cash inflows from investment activities were 23,000,000.00 RMB, while cash outflows were 37,493,636.90 RMB, leading to a net cash flow of -14,493,636.90 RMB from investment activities[54] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,747,072,246.19, an increase of 1.28% from ¥2,712,341,755.90 at the end of the previous year[8] - Total liabilities increased to CNY 1,031,430,007.15 in Q1 2019 from CNY 980,172,142.99 in the previous year, marking an increase of approximately 5.2%[40] - The company's total equity as of March 31, 2019, was CNY 1,625,734,396.21, slightly up from CNY 1,625,617,866.41 at the end of 2018[40] - The company’s total assets amounted to CNY 2.747 billion as of March 31, 2019, compared to CNY 2.712 billion at the end of 2018[34] - Total current assets amounted to CNY 675,172,919.44, with cash and cash equivalents at CNY 28,721,506.86[61] - Total non-current assets reached CNY 1,930,617,089.96, including long-term equity investments of CNY 1,511,338,284.19[61] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 20,892[12] - The company has not conducted an audit for the first quarter report, which may affect the reliability of the financial data presented[63] Operational Costs and Expenses - Total operating costs for Q1 2019 were CNY 138,047,954.69, up from CNY 118,503,228.43, indicating an increase of about 16.5% year-over-year[41] - Research and development expenses for Q1 2019 were CNY 13,196,333.60, compared to CNY 10,453,698.14 in the same period last year, indicating an increase of about 26.4%[41] - The company reported a decrease in income tax expenses by CNY 1.2772 million, a reduction of 57.38%, due to a decrease in total profit[20] - Financial expenses increased by CNY 2.2936 million, a growth of 62.17%, mainly due to increased interest expenses from bank loans and inter-company borrowings[20] - The company incurred financial expenses of CNY 3,876,400.23 in Q1 2019, compared to CNY 2,323,916.14 in Q1 2018, indicating increased borrowing costs[46] Other Financial Metrics - Other comprehensive income decreased by 782.47% year-on-year, primarily due to foreign currency translation adjustments[19] - Cash and cash equivalents increased to CNY 47,948,599.20 as of March 31, 2019, compared to CNY 28,721,506.86 at the end of 2018, reflecting a growth of approximately 67.2%[38] - The company reported sales revenue from goods and services of 42,863,089.85 RMB, an increase from 33,397,782.99 RMB in the previous period, representing a growth of approximately 28.5%[53] - The company reported other income of CNY 145,248.17 in Q1 2019, slightly down from CNY 152,707.91 in Q1 2018[46]

Financial Performance - The company's operating revenue for 2018 was CNY 622,093,848.04, representing a 40.19% increase compared to CNY 443,754,419.40 in 2017[15]. - The net profit attributable to shareholders for 2018 was CNY 69,438,286.13, a significant increase of 78.73% from CNY 38,850,990.10 in 2017[15]. - The basic earnings per share for 2018 was CNY 0.0848, up 78.15% from CNY 0.0476 in 2017[15]. - The company reported a net profit of CNY 137,976,966.72 for the year 2018, a decrease from CNY 319,713,808.01 in 2017, reflecting a decline of approximately 57%[21]. - The company achieved blood product revenue of CNY 326.84 million, a year-on-year increase of 76.56%[60]. - The total revenue for the reporting period was CNY 622.09 million, representing a 40.19% increase compared to CNY 443.75 million in the previous year[67]. Cash Flow and Investments - The net cash flow from operating activities for 2018 was -CNY 84,149,883.86, showing an improvement of 11.60% compared to -CNY 95,194,050.69 in 2017[15]. - Total operating cash inflow increased by 30.87% year-on-year to ¥612,020,524.38, primarily due to increased sales revenue[89]. - Total cash inflow from investing activities decreased by 53.16% year-on-year to ¥38,636,110.73, mainly due to increased cash flow from short-term idle fund management[90]. - Total cash outflow from investing activities decreased by 55.31% year-on-year to ¥86,292,266.70, with no significant investment activities in 2018[90]. - The significant difference between net cash flow from operating activities and net profit was mainly due to asset impairment provisions of ¥73,729,200 and fair value changes of -¥195,666,000[93]. Market and Industry Insights - The company operates in the in-vitro diagnostics (IVD) sector, which accounted for 13% of the global medical device market, with sales reaching USD 52.6 billion in 2017[30]. - The global IVD market size was approximately $60 billion in 2016, with an expected CAGR of about 5%, reaching $78.7 billion by 2021[1]. - China's IVD market size reached approximately 60 billion yuan in 2017, projected to grow to 72.3 billion yuan by 2019, with a CAGR of about 15% over the past five years[1]. - The concentration of the IVD industry in China is low, with over 600 companies, and the top 20 companies holding only about 30% market share, indicating opportunities for growth[5]. Research and Development - The company has developed a microfluidic chip control technology, which is a domestic innovation and internationally leading, with over 20 patents related to this technology[27]. - The company is actively developing new products, with several products approved for market, including rabies immunoglobulin and tetanus immunoglobulin[62]. - The number of R&D personnel increased to 104 in 2018, up from 101 in 2017 and 89 in 2016[83]. - The R&D investment for the year was ¥75,074,298.65, up from ¥58,590,685.81 in the previous year, indicating a growth of approximately 28.3%[84]. Shareholder and Dividend Information - The company plans to distribute cash dividends to shareholders at a rate of CNY 0 per 10 shares, with no bonus shares issued[5]. - The total cash dividend amount for 2018 was ¥0.00, with no shares distributed or increased[130]. - In 2018, the company achieved a net profit of ¥77,508,382.28, with a distributable profit of ¥352,982,877.38, but opted for no cash dividends, resulting in a 0.00% payout ratio[133]. - The company has maintained compliance with relevant laws and regulations regarding profit distribution and shareholder rights[137]. Operational Strategies - The company is focusing on expanding its blood products business and plans to open new plasma collection stations to enhance production capacity[133]. - The blood products business strategy aims to increase operational efficiency and seek reasonable acquisition opportunities to become a competitive player in the industry within 3-5 years[114]. - The company plans to enhance its marketing efforts by integrating sales from different regions and actively participating in drug bidding processes to increase market share[114]. - The company emphasizes the importance of quality control in its operations, establishing a comprehensive quality management system to mitigate risks associated with product safety[117]. Compliance and Commitments - The company has adhered to all commitments made by shareholders and related parties during the reporting period[140]. - No violations of commitments were reported by the company's actual controllers, shareholders, or related parties during the reporting period[140]. - The profit compensation agreement includes a formula for calculating the number of shares to be repurchased based on the difference between committed and actual profits[143].

所有董事均已出席了审议本次季报的董事会会议。 北京博晖创新生物技术股份有限公司 2018 年第三季度报告全文 北京博晖创新生物技术股份有限公司 2018 年第三季度报告 定 2018-06 2018 年 10 月 1 北京博晖创新生物技术股份有限公司 2018 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,531,023,016.65 | 2,737,468,431.65 | | -7.54% | | 归属于上市公司股东的净资产 | 1,113,852,920.84 | 1,474,242,334.41 | | -24.45% | | （元） | | | | | | | 本报告期 | 本报告期比上年同期 增减 | 年初至报告期末 | 年初至报告期末比上 年同期增减 | | 营业收入（元） | ...